文献速递妇科肿瘤

调强放疗对比传统盆腔放疗减少患者报告的慢性毒性:III期试验更新结果

Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial.
PubMed 文献 · J Clin Oncol · 2022-08-12

这项III期试验将279例宫颈癌和子宫内膜癌术后接受盆腔放疗的患者随机分至传统放疗(CRT)或调强放疗(IMRT),中位随访37.8个月。两组总生存、无病生存和局部区域失败无差异,但IMRT组患者报告的慢性胃肠道和泌尿毒性更低。

要点

  • IMRT组与CRT组总生存(P=.53)、无病生存(P=.21)和局部区域失败(P=.81)均无差异。
  • 放疗后1年,CRT组高频腹泻发生率高于IMRT组(15.1% vs 5.8%,P=.042)。
  • 3年时CRT组泌尿功能下降而IMRT组持续改善(EPIC泌尿评分变化均值0.5 vs -6.0,P=.005)。

核心结论

  • IMRT减少患者报告的慢性胃肠道和泌尿毒性,且3年时治疗疗效无差异。

研究设计与样本

  • III期随机对照试验更新分析,纳入279例宫颈癌和子宫内膜癌术后接受盆腔放疗的合格患者,随机分至传统放疗(CRT)或调强放疗(IMRT),中位随访37.8个月,研究时间为2012年至2015年。

主要发现

  • 两组总生存(P=.53)、无病生存(P=.21)和局部区域失败(P=.81)均无差异。
  • 放疗后1年,CRT组高频腹泻发生率高于IMRT组(15.1% vs 5.8%,P=.042)。
  • 放疗后1年,CRT组每日需服用止泻药两次及以上者多于IMRT组(8.6% vs 1.2%,P=.036)。
  • 3年时CRT组报告泌尿功能下降,而IMRT组持续改善(EPIC泌尿评分变化均值0.5,标准差13.0,IMRT vs -6.0,标准差14.3,CRT,P=.005)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The purpose of this update was to determine differences in patient-reported chronic toxicity and disease outcomes with intensity-modulated radiation therapy (IMRT) compared with conventional pelvic radiation. Patients with cervical and endometrial cancers who received postoperative pelvic radiation were randomly assigned to conventional radiation therapy (CRT) or IMRT. Toxicity and quality of life were assessed using Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Expanded Prostate Cancer Index Composite (EPIC) bowel and urinary domains, and Functional Assessment of Cancer Therapy-General. Between 2012 and 2015, 279 eligible patients were enrolled to the study with a median follow-up of 37.8 months. There were no differences in overall survival (P = .53), disease-free survival (P = .21), or locoregional failure (P = .81). One year after RT, patients in the CRT arm experienced more high-level diarrhea frequency (5.8% IMRT v 15.1% CRT, P = .042) and a greater number had to take antidiarrheal medication two or more times a day (1.2% IMRT v 8.6% CRT, P = .036). At 3 years, women in the CRT arm reported a decline in urinary function, whereas the IMRT arm continued to improve (mean change in EPIC urinary score = 0.5, standard deviation = 13.0, IMRT v -6.0, standard deviation = 14.3, CRT, P = .005). In conclusion, IMRT reduces patient-reported chronic GI and urinary toxicity with no difference in treatment efficacy at 3 years.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yeung AR, Deshmukh S, Klopp AH, et al. Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial. J Clin Oncol. 2022. PMID: 35960897. doi:10.1200/JCO.21.02831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。